164 related articles for article (PubMed ID: 31473468)
41. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
[TBL] [Abstract][Full Text] [Related]
42. Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019.
Schjesvold F
Eur J Haematol; 2020 Oct; 105(4):434-448. PubMed ID: 32557833
[TBL] [Abstract][Full Text] [Related]
43. Influence of Treating Facility, Provider Volume, and Patient-Sharing on Survival of Patients With Multiple Myeloma.
Freeman AT; Kuo M; Zhou L; Trogdon JG; Baggett CD; Tuchman SA; Shea TC; Wood WA
J Natl Compr Canc Netw; 2019 Sep; 17(9):1100-1108. PubMed ID: 31487686
[TBL] [Abstract][Full Text] [Related]
44. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Hájek R; Jarkovsky J; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Campioni M; DeCosta L; Treur M; Gonzalez-McQuire S; Bouwmeester W
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e219-e240. PubMed ID: 29793653
[TBL] [Abstract][Full Text] [Related]
45. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
46. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
Jagannath S; Abonour R; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Agarwal A; Srinivasan S; Kitali A; Flick ED; Sturniolo M; Rifkin RM
Blood Adv; 2018 Jul; 2(13):1608-1615. PubMed ID: 29986853
[TBL] [Abstract][Full Text] [Related]
47. [Role of stem cell transplantation in treatment of multiple myeloma].
Shimazaki C
Nihon Rinsho; 2007 Dec; 65(12):2338-44. PubMed ID: 18069280
[TBL] [Abstract][Full Text] [Related]
48. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.
Paquin AR; Kumar SK; Buadi FK; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Hwa L; Fonder A; Hobbs M; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Rajkumar SV
Blood Cancer J; 2018 Dec; 8(12):125. PubMed ID: 30538223
[TBL] [Abstract][Full Text] [Related]
49. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
50. [Epidemiology of multiple myeloma in city Moscow].
Vinogradova OY; Ptushkin VV; Chernikov MV; Kochkareva YB; Zherebtsova VA
Ter Arkh; 2019 Jul; 91(7):83-92. PubMed ID: 32598740
[TBL] [Abstract][Full Text] [Related]
51. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
Straka C; Knop S; Vogel M; Müller J; Kropff M; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Salwender H; Wandt H; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Fischer T; Liebisch P; Engelhardt M; Einsele H
Eur J Haematol; 2019 Sep; 103(3):255-267. PubMed ID: 31231828
[TBL] [Abstract][Full Text] [Related]
52. Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
Katodritou E; Kastritis E; Gatt M; Cohen YC; Avivi I; Pouli A; Lalayianni C; Lavi N; Delimpasis S; Kyrtsonis MC; Michael M; Suriu C; Miri Z; Tzafarti K; Vadikoliou C; Maltezas D; Zikos P; Ganzel C; Vaxman Y; Aviv A; Christoforidou A; Gavriatopoulou M; Shaulov A; Verrou E; Papanota AM; Fakinos G; Gkioka AI; Palaska V; Triantafyllou T; Konstantinidou P; Anagnostopoulos A; Terpos E; Dimopoulos MA
Am J Hematol; 2020 May; 95(5):465-471. PubMed ID: 32048329
[TBL] [Abstract][Full Text] [Related]
53. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
[TBL] [Abstract][Full Text] [Related]
54. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
55. [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
Kehrer M; Koob S; Strauss A; Wirtz DC; Schmolders J
Z Orthop Unfall; 2017 Oct; 155(5):575-586. PubMed ID: 28806822
[No Abstract] [Full Text] [Related]
56. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
Muta T; Miyamoto T; Fujisaki T; Ohno Y; Kamimura T; Kato K; Takenaka K; Iwasaki H; Eto T; Takamatsu Y; Teshima T; Akashi K;
Intern Med; 2013; 52(1):63-70. PubMed ID: 23291675
[TBL] [Abstract][Full Text] [Related]
58. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
59. Improved survival of older patients with multiple myeloma in the era of novel agents.
Mey UJ; Leitner C; Driessen C; Cathomas R; Klingbiel D; Hitz F
Hematol Oncol; 2016 Dec; 34(4):217-223. PubMed ID: 25898820
[TBL] [Abstract][Full Text] [Related]
60. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
